We narrowed to 272 results for: Kars

#100061-AAV9

Ready-to-use AAV9 particles produced from pAAV-Ef1a-DIO C1V1 (t/t)-TS-mCherry (PV2670) (#100061). In addition to the viral particles, you will also receive purified pAAV-Ef1a-DIO C1V1 (t/t)-TS-mCherry (PV2670) plasmid DNA. EFIa-driven, Cre-dependent, C1V1 (t/t) fused to mCherry for optogenetic activation. These AAV preparations are suitable purity for injection into animals.

Karl Deisseroth

April 6, 2018

Academic Institutions and Nonprofits only

#20949-AAV9

Ready-to-use AAV9 particles produced from pAAV-double floxed-eNpHR-EYFP-WPRE-pA (#20949). In addition to the viral particles, you will also receive purified pAAV-double floxed-eNpHR-EYFP-WPRE-pA plasmid DNA. EF1a-driven, cre-dependent eNpHR EYFP for optogenetic inhibition. These AAV preparations are suitable purity for injection into animals.

Karl Deisseroth

July 12, 2018

Academic Institutions and Nonprofits only

#27056-AAVrg

Ready-to-use AAV Retrograde particles produced from pAAV-Ef1a-DIO EYFP (#27056). In addition to the viral particles, you will also receive purified pAAV-Ef1a-DIO EYFP plasmid DNA. EF1a-driven, Cre-dependent EYFP expression. These AAV were produced with a retrograde serotype, which permits retrograde access to projection neurons. These AAV preparations are suitable purity for injection into animals.

Karl Deisseroth

Jan. 10, 2020

Academic Institutions and Nonprofits only

#177672-AAV8

Ready-to-use AAV8 particles produced from pAAV-nEF-Con/Fon DREADD Gi-mCherry (#177672). In addition to the viral particles, you will also receive purified pAAV-nEF-Con/Fon DREADD Gi-mCherry plasmid DNA. nEF-driven, Cre- and Flp-dependent hM4D(Gi) receptor with an mCherry reporter for CNO-induced neuronal inhibition. These AAV preparations are suitable purity for injection into animals.

Karl Deisseroth

Feb. 27, 2024

Academic Institutions and Nonprofits only

#26973-AAVrg

Ready-to-use AAV Retrograde particles produced from pAAV-hSyn-hChR2(H134R)-EYFP (#26973). In addition to the viral particles, you will also receive purified pAAV-hSyn-hChR2(H134R)-EYFP plasmid DNA. hSyn-driven, humanized channelrhodopsin H134R mutant fused to EYFP for optogenetic activation. These AAV were produced with a retrograde serotype, which permits retrograde access to projection neurons. These AAV preparations are suitable purity for injection into animals.

Karl Deisseroth

Oct. 9, 2019

Academic Institutions and Nonprofits only

#26973-PHPeB

Ready-to-use AAV PHP.eB particles produced from pAAV-hSyn-hChR2(H134R)-EYFP (#26973). In addition to the viral particles, you will also receive purified pAAV-hSyn-hChR2(H134R)-EYFP plasmid DNA. hSyn-driven, humanized channelrhodopsin H134R mutant fused to EYFP for optogenetic activation. These AAV were produced with the PHPeB serotype, which permits efficient transduction of the central nervous system. These AAV preparations are suitable purity for injection into animals.

Karl Deisseroth

Sept. 8, 2020

Academic Institutions and Nonprofits only

#26975-AAVrg

Ready-to-use AAV Retrograde particles produced from pAAV-CaMKIIa-hChR2(H134R)-mCherry (#26975). In addition to the viral particles, you will also receive purified pAAV-CaMKIIa-hChR2(H134R)-mCherry plasmid DNA. CamKIIa-driven, humanized channelrhodopsin H134R mutant fused to mCherry for optogenetic activation. These AAV were produced with a retrograde serotype, which permits retrograde access to projection neurons. These AAV preparations are suitable purity for injection into animals.

Karl Deisseroth

Dec. 2, 2019

Academic Institutions and Nonprofits only

#177673-AAV8

Ready-to-use AAV8 particles produced from pAAV-nEF-Con/Foff DREADD Gi-mCherry (#177673). In addition to the viral particles, you will also receive purified pAAV-nEF-Con/Foff DREADD Gi-mCherry plasmid DNA. nEF-driven hM4D(Gi) receptor with an mCherry reporter for CNO-induced neuronal inhibition only in Cre expressing cells and not in Flp expressing cells. These AAV preparations are suitable purity for injection into animals.

Karl Deisseroth

Feb. 16, 2024

Academic Institutions and Nonprofits only

#20297-AAV9

Ready-to-use AAV9 particles produced from pAAV-EF1a-double floxed-hChR2(H134R)-mCherry-WPRE-HGHpA (#20297). In addition to the viral particles, you will also receive purified pAAV-EF1a-double floxed-hChR2(H134R)-mCherry-WPRE-HGHpA plasmid DNA. Humanized channelrhodopsin H134R mutant fused to mCherry, driven by the EF1a promoter. Cre-dependent. These AAV preparations are suitable purity for injection into animals.

Karl Deisseroth

March 15, 2018

Academic Institutions and Nonprofits only

#20297-AAV5

Ready-to-use AAV5 particles produced from pAAV-EF1a-double floxed-hChR2(H134R)-mCherry-WPRE-HGHpA (#20297). In addition to the viral particles, you will also receive purified pAAV-EF1a-double floxed-hChR2(H134R)-mCherry-WPRE-HGHpA plasmid DNA. Humanized channelrhodopsin H134R mutant fused to mCherry, driven by the EF1a promoter. Cre-dependent. These AAV preparations are suitable purity for injection into animals.

Karl Deisseroth

Feb. 15, 2018

Academic Institutions and Nonprofits only

#20297-AAV1

Ready-to-use AAV1 particles produced from pAAV-EF1a-double floxed-hChR2(H134R)-mCherry-WPRE-HGHpA (#20297). In addition to the viral particles, you will also receive purified pAAV-EF1a-double floxed-hChR2(H134R)-mCherry-WPRE-HGHpA plasmid DNA. Humanized channelrhodopsin H134R mutant fused to mCherry, driven by the EF1a promoter. Cre-dependent. These AAV preparations are suitable purity for injection into animals.

Karl Deisseroth

Feb. 15, 2018

Academic Institutions and Nonprofits only

#20297-AAV8

Ready-to-use AAV8 particles produced from pAAV-EF1a-double floxed-hChR2(H134R)-mCherry-WPRE-HGHpA (#20297). In addition to the viral particles, you will also receive purified pAAV-EF1a-double floxed-hChR2(H134R)-mCherry-WPRE-HGHpA plasmid DNA. Humanized channelrhodopsin H134R mutant fused to mCherry, driven by the EF1a promoter. Cre-dependent. These AAV preparations are suitable purity for injection into animals.

Karl Deisseroth

Dec. 18, 2017

Academic Institutions and Nonprofits only

#20298-AAV9

Ready-to-use AAV9 particles produced from pAAV-EF1a-double floxed-hChR2(H134R)-EYFP-WPRE-HGHpA (#20298). In addition to the viral particles, you will also receive purified pAAV-EF1a-double floxed-hChR2(H134R)-EYFP-WPRE-HGHpA plasmid DNA. EF1a-driven, Cre-dependent, humanized channelrhodopsin H134R mutant fused to EYFP, for optogenetic activation. These AAV preparations are suitable purity for injection into animals.

Karl Deisseroth

March 30, 2018

Academic Institutions and Nonprofits only

#20298-AAV5

Ready-to-use AAV5 particles produced from pAAV-EF1a-double floxed-hChR2(H134R)-EYFP-WPRE-HGHpA (#20298). In addition to the viral particles, you will also receive purified pAAV-EF1a-double floxed-hChR2(H134R)-EYFP-WPRE-HGHpA plasmid DNA. EF1a-driven, Cre-dependent, humanized channelrhodopsin H134R mutant fused to EYFP, for optogenetic activation. These AAV preparations are suitable purity for injection into animals.

Karl Deisseroth

Feb. 15, 2018

Academic Institutions and Nonprofits only

#20298-AAVrg

Ready-to-use AAV Retrograde particles produced from pAAV-EF1a-double floxed-hChR2(H134R)-EYFP-WPRE-HGHpA (#20298). In addition to the viral particles, you will also receive purified pAAV-EF1a-double floxed-hChR2(H134R)-EYFP-WPRE-HGHpA plasmid DNA. These AAV were produced with a retrograde serotype, which permits retrograde access to projection neurons. These AAV preparations are suitable purity for injection into animals.

Karl Deisseroth

Oct. 12, 2017

Academic Institutions and Nonprofits only

#20298-AAV1

Ready-to-use AAV1 particles produced from pAAV-EF1a-double floxed-hChR2(H134R)-EYFP-WPRE-HGHpA (#20298). In addition to the viral particles, you will also receive purified pAAV-EF1a-double floxed-hChR2(H134R)-EYFP-WPRE-HGHpA plasmid DNA. EF1a-driven, Cre-dependent, humanized channelrhodopsin H134R mutant fused to EYFP, for optogenetic activation. These AAV preparations are suitable purity for injection into animals.

Karl Deisseroth

Oct. 12, 2017

Academic Institutions and Nonprofits only

#26968-AAV9

Ready-to-use AAV9 particles produced from pAAV-Ef1a-DIO ChETA-EYFP (#26968). In addition to the viral particles, you will also receive purified pAAV-Ef1a-DIO ChETA-EYFP plasmid DNA. EF1a-driven, Cre-dependent, ChETA fused to EYFP for optogenetic activation. These AAV preparations are suitable purity for injection into animals.

Karl Deisseroth

Gunaydin et al Nat Neurosci. 2010 Mar;13(3):387-92. doi

March 30, 2018

Academic Institutions and Nonprofits only

#20297-AAVrg

Ready-to-use AAV Retrograde particles produced from pAAV-EF1a-double floxed-hChR2(H134R)-mCherry-WPRE-HGHpA (#20297). In addition to the viral particles, you will also receive purified pAAV-EF1a-double floxed-hChR2(H134R)-mCherry-WPRE-HGHpA plasmid DNA. Humanized channelrhodopsin H134R mutant fused to mCherry, driven by the EF1a promoter. Cre-dependent. These AAV were produced with a retrograde serotype, which permits retrograde access to projection neurons. These AAV preparations are suitable purity for injection into animals.

Karl Deisseroth

Aug. 22, 2017

Academic Institutions and Nonprofits only

#26968-AAV1

Ready-to-use AAV1 particles produced from pAAV-Ef1a-DIO ChETA-EYFP (#26968). In addition to the viral particles, you will also receive purified pAAV-Ef1a-DIO ChETA-EYFP plasmid DNA. EF1a-driven, Cre-dependent, ChETA fused to EYFP for optogenetic activation. These AAV preparations are suitable purity for injection into animals.

Karl Deisseroth

Gunaydin et al Nat Neurosci. 2010 Mar;13(3):387-92. doi

Feb. 21, 2018

Academic Institutions and Nonprofits only

#26968-AAV5

Ready-to-use AAV5 particles produced from pAAV-Ef1a-DIO ChETA-EYFP (#26968). In addition to the viral particles, you will also receive purified pAAV-Ef1a-DIO ChETA-EYFP plasmid DNA. EF1a-driven, Cre-dependent, ChETA fused to EYFP for optogenetic activation. These AAV preparations are suitable purity for injection into animals.

Karl Deisseroth

Gunaydin et al Nat Neurosci. 2010 Mar;13(3):387-92. doi

Feb. 20, 2018

Academic Institutions and Nonprofits only

#20298-PHPeB

Ready-to-use AAV PHP.eB particles produced from pAAV-EF1a-double floxed-hChR2(H134R)-EYFP-WPRE-HGHpA (#20298). In addition to the viral particles, you will also receive purified pAAV-EF1a-double floxed-hChR2(H134R)-EYFP-WPRE-HGHpA plasmid DNA. EF1a-driven, Cre-dependent, humanized channelrhodopsin H134R mutant fused to EYFP, for optogenetic activation. These AAV were produced with the PHPeB serotype, which permits efficient transduction of the central nervous system. These AAV preparations are suitable purity for injection into animals.

Karl Deisseroth

Sept. 8, 2020

Academic Institutions and Nonprofits only

#26969-AAV5

Ready-to-use AAV5 particles produced from pAAV-CaMKIIa-hChR2(H134R)-EYFP (#26969). In addition to the viral particles, you will also receive purified pAAV-CaMKIIa-hChR2(H134R)-EYFP plasmid DNA. CaMKIIa-driven, humanized channelrhodopsin H134R mutant fused to EYFP for optogenetic activation. These AAV preparations are suitable purity for injection into animals.

Karl Deisseroth

Lee et al Nature. 2010 Jun 10. 465(7299):788-92.

March 7, 2018

Academic Institutions and Nonprofits only

#26969-AAV9

Ready-to-use AAV9 particles produced from pAAV-CaMKIIa-hChR2(H134R)-EYFP (#26969). In addition to the viral particles, you will also receive purified pAAV-CaMKIIa-hChR2(H134R)-EYFP plasmid DNA. CaMKIIa-driven, humanized channelrhodopsin H134R mutant fused to EYFP for optogenetic activation. These AAV preparations are suitable purity for injection into animals.

Karl Deisseroth

Lee et al Nature. 2010 Jun 10. 465(7299):788-92.

March 7, 2018

Academic Institutions and Nonprofits only

#26966-AAV5

Ready-to-use AAV5 particles produced from pAAV-Ef1a-DIO eNpHR 3.0-EYFP (#26966). In addition to the viral particles, you will also receive purified pAAV-Ef1a-DIO eNpHR 3.0-EYFP plasmid DNA. EF1a-driven, cre-dependent eNpHR 3.0-EYFP for optogenetic inhibition. These AAV preparations are suitable purity for injection into animals.

Karl Deisseroth

Gradinaru et al Cell. 2010 Apr 2. 141(1):154-65.

Feb. 14, 2018

Academic Institutions and Nonprofits only

#26969-AAV1

Ready-to-use AAV1 particles produced from pAAV-CaMKIIa-hChR2(H134R)-EYFP (#26969). In addition to the viral particles, you will also receive purified pAAV-CaMKIIa-hChR2(H134R)-EYFP plasmid DNA. CaMKIIa-driven, humanized channelrhodopsin H134R mutant fused to EYFP for optogenetic activation. These AAV preparations are suitable purity for injection into animals.

Karl Deisseroth

Lee et al Nature. 2010 Jun 10. 465(7299):788-92.

May 9, 2018

Academic Institutions and Nonprofits only

#26966-AAV9

Ready-to-use AAV9 particles produced from pAAV-Ef1a-DIO eNpHR 3.0-EYFP (#26966). In addition to the viral particles, you will also receive purified pAAV-Ef1a-DIO eNpHR 3.0-EYFP plasmid DNA. EF1a-driven, cre-dependent eNpHR 3.0-EYFP for optogenetic inhibition. These AAV preparations are suitable purity for injection into animals.

Karl Deisseroth

Gradinaru et al Cell. 2010 Apr 2. 141(1):154-65.

April 6, 2018

Academic Institutions and Nonprofits only

#183535-AAV8

Ready-to-use AAV8 particles produced from pAAV-CaMKIIa-Flpo (#183535). In addition to the viral particles, you will also receive purified pAAV-CaMKIIa-Flpo plasmid DNA. CamKIIa-driven expression of Flpo recombinase. These AAV preparations are suitable purity for injection into animals.

Karl Deisseroth

Fan et al Cell. 2023 Feb 2;186(3):543-559.e19. doi

Oct. 8, 2025

Academic Institutions and Nonprofits only

#131000-AAV8

Ready-to-use AAV8 particles produced from pAAV-CaMKIIa-mScarlet (#131000). In addition to the viral particles, you will also receive purified pAAV-CaMKIIa-mScarlet plasmid DNA. CamKIIa-driven expression of mScarlet. These AAV preparations are suitable purity for injection into animals.

Karl Deisseroth

Marshel et al Science. 2019 Aug 9;365(6453). pii: scie

Sept. 27, 2023

Academic Institutions and Nonprofits only

#131001-AAV1

Ready-to-use AAV1 particles produced from pAAV-hSyn-mScarlet (#131001). In addition to the viral particles, you will also receive purified pAAV-hSyn-mScarlet plasmid DNA. Synapsin-driven mScarlet control vector. These AAV preparations are suitable purity for injection into animals.

Karl Deisseroth

Marshel et al Science. 2019 Aug 9;365(6453). pii: scie

Nov. 29, 2021

Academic Institutions and Nonprofits only

#131001-AAV8

Ready-to-use AAV8 particles produced from pAAV-hSyn-mScarlet (#131001). In addition to the viral particles, you will also receive purified pAAV-hSyn-mScarlet plasmid DNA. Synapsin-driven mScarlet control vector. These AAV preparations are suitable purity for injection into animals.

Karl Deisseroth

Marshel et al Science. 2019 Aug 9;365(6453). pii: scie

Sept. 27, 2023

Academic Institutions and Nonprofits only

#26966-AAV1

Ready-to-use AAV1 particles produced from pAAV-Ef1a-DIO eNpHR 3.0-EYFP (#26966). In addition to the viral particles, you will also receive purified pAAV-Ef1a-DIO eNpHR 3.0-EYFP plasmid DNA. EF1a-driven, cre-dependent eNpHR 3.0-EYFP for optogenetic inhibition. These AAV preparations are suitable purity for injection into animals.

Karl Deisseroth

Gradinaru et al Cell. 2010 Apr 2. 141(1):154-65.

Feb. 14, 2018

Academic Institutions and Nonprofits only

#26969-AAV2

Ready-to-use AAV2 particles produced from pAAV-CaMKIIa-hChR2(H134R)-EYFP (#26969). In addition to the viral particles, you will also receive purified pAAV-CaMKIIa-hChR2(H134R)-EYFP plasmid DNA. CaMKIIa-driven, humanized channelrhodopsin H134R mutant fused to EYFP for optogenetic activation. These AAV preparations are suitable purity for injection into animals.

Karl Deisseroth

Lee et al Nature. 2010 Jun 10. 465(7299):788-92.

Feb. 14, 2018

Academic Institutions and Nonprofits only

#55637-AAV1

Ready-to-use AAV1 particles produced from pAAV-EF1a-Flpo (#55637). In addition to the viral particles, you will also receive purified pAAV-EF1a-Flpo plasmid DNA. EF1a-driven Flpo recombinase expression. These AAV preparations are suitable purity for injection into animals.

Karl Deisseroth

Fenno et al Nat Methods. 2014 Jul;11(7):763-72. doi:

July 8, 2019

Academic Institutions and Nonprofits only

#131002-AAV5

Ready-to-use AAV5 particles produced from pAAV-Ef1a-DIO mScarlet (#131002). In addition to the viral particles, you will also receive purified pAAV-Ef1a-DIO mScarlet plasmid DNA. EF1a-driven, Cre-dependent mScarlet expression. These AAV preparations are suitable purity for injection into animals.

Karl Deisseroth

Marshel et al Science. 2019 Aug 9;365(6453). pii: scie

Sept. 27, 2024

Academic Institutions and Nonprofits only

#55636-AAV11

Ready-to-use AAV11 particles produced from pAAV-EF1a-Cre (#55636). In addition to the viral particles, you will also receive purified pAAV-EF1a-Cre plasmid DNA. EF1a-driven expression of Cre recombinase. These AAV preparations are suitable purity for injection into animals.

Karl Deisseroth

Fenno et al Nat Methods. 2014 Jul;11(7):763-72. doi:

July 16, 2025

Academic Institutions and Nonprofits only

#55638-AAV8

Ready-to-use AAV8 particles produced from pAAV-EF1a-vCre (#55638). In addition to the viral particles, you will also receive purified pAAV-EF1a-vCre plasmid DNA. EF1a-driven expression of VCre. These AAV preparations are suitable purity for injection into animals.

Karl Deisseroth

Fenno et al Nat Methods. 2014 Jul;11(7):763-72. doi:

Nov. 12, 2020

Academic Institutions and Nonprofits only

#131002-AAV1

Ready-to-use AAV1 particles produced from pAAV-Ef1a-DIO mScarlet (#131002). In addition to the viral particles, you will also receive purified pAAV-Ef1a-DIO mScarlet plasmid DNA. EF1a-driven, Cre-dependent mScarlet expression. These AAV preparations are suitable purity for injection into animals.

Karl Deisseroth

Marshel et al Science. 2019 Aug 9;365(6453). pii: scie

Nov. 29, 2021

Academic Institutions and Nonprofits only

#28017-AAVrg

Ready-to-use AAV Retrograde particles produced from AAV-CAG-hChR2-H134R-tdTomato (#28017). In addition to the viral particles, you will also receive purified AAV-CAG-hChR2-H134R-tdTomato plasmid DNA. Humanized channelrhodopsin H134R mutant fused to tdTomato, under the control of the CAG promoter. These AAV were produced with a retrograde serotype, which permits retrograde access to projection neurons. These AAV preparations are suitable purity for injection into animals.

Karel Svoboda

Mao et al Neuron. 2011 Oct 6;72(1):111-23.

June 20, 2017

Academic Institutions and Nonprofits only

#35499-AAV9

Ready-to-use AAV9 particles produced from pAAV-CaMKIIa-C1V1 (t/t)-TS-EYFP (#35499). In addition to the viral particles, you will also receive purified pAAV-CaMKIIa-C1V1 (t/t)-TS-EYFP plasmid DNA. CaMKIIa-driven, C1V1 (t/t) fused to EYFP for optogenetic activation. These AAV preparations are suitable purity for injection into animals.

Karl Deisseroth

Yizhar et al Nature. 2011 Jul 27;477(7363):171-8. doi

April 6, 2018

Academic Institutions and Nonprofits only

#55637-AAV2

Ready-to-use AAV2 particles produced from pAAV-EF1a-Flpo (#55637). In addition to the viral particles, you will also receive purified pAAV-EF1a-Flpo plasmid DNA. EF1a-driven Flpo recombinase expression. These AAV preparations are suitable purity for injection into animals.

Karl Deisseroth

Fenno et al Nat Methods. 2014 Jul;11(7):763-72. doi:

March 18, 2024

Academic Institutions and Nonprofits only